Vascular complications in a 51-year-old female with a primary antiphospholipd syndrome - A case report;Powikłania naczyniowe u 51-letniej chorej z pierwotnym zespołem antyfosfolipidowym - Opis przypadku

Kardiologia Polska

Volumn 65, Issue 1, 2007, Pages 50-53

  Wieteska, Maria ^a   Szturmowicz, Monika ^a   Kurzyna, Marcin ^a   Hajduk, Bogdan ^a   Biederman, Andrzej ^b   Torbicki, Adam ^a  

^a INSTYTUT GRU LICY I CHORÓB P UC   (Poland)

^b INSTITUTE OF CARDIOLOGY   (Poland)

Author keywords

Antiphospholipid syndrome (APS); Chronic thromboembolic pulmonary hypertension (CTEPH); Pulmonary thromboendarterectomy

Indexed keywords

ADULT; ANGIOCARDIOGRAPHY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CASE REPORT; CLINICAL FEATURE; CORONARY ARTERY DISEASE; CORONARY STENT; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DISEASE SEVERITY; DYSPNEA; ELECTROCARDIOGRAPHY MONITORING; ENDARTERECTOMY; FEMALE; HOSPITAL ADMISSION; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; PULMONARY HYPERTENSION; THORAX PAIN; THROMBOEMBOLISM; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 33846875456     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Musiał J. Zespół antyfosfolipidowy. In: Łopaciuk S (ed.). Zakrzepy i zatory. PZWL, Warszawa 2002; 89-104.
2. Thomas RH. Hypercoagulability syndromes. Arch Intern Med 2001; 161: 2433-9.
3. Ortel TL. Thrombosis and the antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program 2005; 462-8.
4. Wygonowska EM, Zdrodowska-Stefanow B. Zespół antyfosfolipidowy. Wiad Lek 2005; 58: 116-23.
5. Wilson WA, Ghravi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-11.
6. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
7. Cuadrado MJ. Treatment and monitoring of patients with antiphospholipid antibodies and thrombotic history (Hughes syndrome). Curr Rheumatol Rep 2002; 4: 392-8.
8. Moll S, Ortel TL. Antiphospholipid antibodies. Arch Intern Med 2002; 162: 1783-4.
9. Khamashta MA, Hunt JB. Moderate dose oral anticoagulant therapy in patient with antiphospholipid syndrome? No. J Thromb Haemost 2005; 3: 844-5.
10. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3: 848-3.
11. Crowtther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-8.
12. Büller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Supl. 3): 401S-428S.
13. Doyle RL, McCrory D, Channik RN, et al. Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126 (Sup. 1): 63S-71S.